Objectives. Effective treatment of laryngeal cancer requires clinical decision-making that balances survival outcomes with the preservation of essential functions, such as voice and swallowing. This study, led by the Clinical Practice Guideline Committee of the Korean Society of Head and Neck Surgery, aims to establish evidence-based recommendations to guide surgeons in optimizing treatment decisions for patients with laryngeal cancer.Methods. A literature search was performed in the PubMed, Embase, Cochrane Library, and KoreaMed databases by a literature search expert and subsequently reviewed by a panel of 39 committee experts. The Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) method was employed to assess the quality of evidence and develop and report the recommendations. The strength of each recommendation reflects the guideline panel’s confidence that the benefits of an intervention outweigh its risks for the target population. After drafting the guidelines, Delphi questionnaires were distributed to members of the Korean Society of Head and Neck Surgery and an external reviewer panel.Results. In total, 15 evidence-based recommendations are provided, addressing six critical aspects of laryngeal cancer treatment: early-stage treatment, treatment of locally advanced cancer, neck management, adjuvant therapy, swallowing rehabilitation, and salvage treatment for recurrent tumors.Conclusion. The guidelines provide evidence-based, validated recommendations to support clinicians in making optimal treatment decisions for laryngeal cancer.
Background: Burning mouth syndrome (BMS) is a chronic orofacial pain disorder characterized by persistent intraoral burning recurring daily for at least 2 h over more than 3 months, without explanatory mucosal or laboratory findings. It affects 1.7–7.7% of the population, predominantly perimenopausal and postmenopausal women, and conventional pharmacotherapy offers only partial relief. Aim: This narrative review examines the associative and mechanistic evidence linking the oral microbiome to BMS and evaluates the rationale for lactic acid bacteria (LAB) as a candidate therapeutic strategy. Methods: PubMed/MEDLINE, Scopus, and Web of Science were searched for English-language literature on BMS, the oral microbiome, and probiotics, supplemented by mechanistic data from related conditions. Results: BMS patients may exhibit a compositionally distinct salivary microbiome, with reduced alpha diversity in psychiatric-comorbid subsets, though findings are heterogeneous. LAB, particularly Lacticaseibacillus paracasei, show antimicrobial and immunomodulatory properties relevant to oral homeostasis, but direct clinical evidence in BMS remains scarce and largely preclinical. Conclusions: Current evidence is predominantly cross-sectional and associative; the oral dysbiosis–BMS link and the therapeutic potential of LAB should be regarded as hypothesis-generating, warranting biomarker-anchored, strain-specific randomized trials.